journal article·2013-05-08

Multifunctional Hierarchically Assembled Nanostructures as Complex Stage-Wise Dual-Delivery Systems for Coincidental Yet Differential Trafficking of siRNA and Paclitaxel

Mahmoud Elsabahy, Ritu Shrestha, Corrie Clark, Sara Taylor, Jeffrey Leonard, Karen L. Wooley

Nano Letters· Volume 13· Issue 5
Publisher page

Abstract

Development of multifunctional nanostructures that can be tuned to codeliver multiple drugs and diagnostic agents to diseased tissues is of great importance. Hierarchically assembled theranostic (HAT) nanostructures based on anionic cylindrical shell cross-linked nanoparticles and cationic shell cross-linked knedel-like nanoparticles (cSCKs) have recently been developed by our group to deliver siRNA intracellularly and to undergo radiolabeling. In the current study, paclitaxel, a hydrophobic anticancer drug, and siRNA have been successfully loaded into the cylindrical and spherical components of the hierarchical assemblies, respectively. Cytotoxicity, immunotoxicity, and intracellular delivery mechanism of the HAT nanostructures and their individual components have been investigated. Decoration of nanoparticles with F3-tumor homing peptide was shown to enhance the selective cellular uptake of the spherical particles, whereas the HAT nanoassemblies underwent an interesting disassembly process in contact with either OVCAR-3 or RAW 264.7 cell lines. The HAT nanostructures were found to "stick" to the cell membrane and "trigger" the release of spherical cSCKs templated onto their surfaces intracellularly, while retaining the cylindrical part on the cell surface. Combination of paclitaxel and cell-death siRNA (siRNA that induces cell death) into the HAT nanostructures resulted in greater reduction in cell viability than siRNA complexed with Lipofectamine and the assemblies loaded with the individual drugs. In addition, a shape-dependent immunotoxicity was observed for both spherical and cylindrical nanoparticles with the latter being highly immunotoxic. Supramolecular assembly of the two nanoparticles into the HAT nanostructures significantly reduced the immunotoxicity of both cSCKs and cylinders. HAT nanostructures decorated with targeting moieties, loaded with nucleic acids, hydrophobic drugs, radiolabels, and fluorophores, with control over their toxicity, immunotoxicity, and intracellular delivery might have great potential for biomedical delivery applications.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Department of Chemical Engineering, Laboratory for Synthetic-Biologic Interactions, Texas A&M University, P.O. Box 30012, 3255 TAMU, College Station, Texas 77842-3012, United States

Department of Pharmaceutics, Faculty of Pharmacy, Assiut International Center of Nanomedicine, Al-Rajhy Liver Hospital, Assiut University, Assiut, Egypt

Department of Neurological Surgery, Washington University and St. Louis Children’s Hospital, St. Louis Missouri, 63110, United States

References (50)

Show source-provided references
1. Elsabahy M. · Chem. Soc. Rev. · 2012 · 41 · 254510.1039/c2cs15327k ↗
2. Chen Y. · Mol. Ther. · 2010 · 18 · 82810.1038/mt.2009.291 ↗
3. Xiong X. B. · ACS Nano · 2011 · 5 · 520210.1021/nn2013707 ↗
4. Sun T. M. · ACS Nano · 2011 · 5 · 148310.1021/nn103349h ↗
5. Lee J. H. · Angew. Chem., Int. Ed. · 2009 · 48 · 417410.1002/anie.200805998 ↗
6. Yu Y. H. · Eur. J. Pharm. Biopharm. · 2012 · 80 · 26810.1016/j.ejpb.2011.11.002 ↗
7. Bhattarai S. R. · Pharm. Res. · 2010 · 27 · 255610.1007/s11095-010-0245-0 ↗
8. Chen A. M. · Small · 2009 · 5 · 267310.1002/smll.200900621 ↗
9. 10.1039/c3cs60064e10.1039/c3cs60064e ↗
10. Lammers T. · Mol. Pharm. · 2010 · 7 · 189910.1021/mp100228v ↗
11. Nystrom A. M. · Acc. Chem. Res. · 2011 · 44 · 96910.1021/ar200097k ↗
12. Shrestha R. · Bioconjugate Chem. · 2012 · 23 · 57410.1021/bc200629f ↗
13. Zhang S. · J. Am. Chem. Soc. · 2012 · 134 · 1846710.1021/ja309037m ↗
14. Li A. · ACS Nano · 2012 · 6 · 897010.1021/nn303030t ↗
15. Sun G. · J. Am. Chem. Soc. · 2011 · 133 · 853410.1021/ja200182t ↗
16. Lin L. Y. · J. Controlled Release · 2011 · 152 · 3710.1016/j.jconrel.2011.01.009 ↗
17. Li Z. · J. Am. Chem. Soc. · 2011 · 133 · 122810.1021/ja109191z ↗
18. Sun G. · ACS Nano · 2009 · 3 · 67310.1021/nn8007977 ↗
19. Oba M. · Mol. Pharmaceutics · 2008 · 5 · 108010.1021/mp800070s ↗
20. Fujimoto T. · J. Cell. Sci. · 2000 · 113 · 350910.1242/jcs.113.19.3509 ↗
21. Kim J. O. · Biomacromolecules · 2010 · 11 · 91910.1021/bm9013364 ↗
22. Elsabahy M. · J. Polym. Sci. Part A: Polym. Chem. · 2012 · 50 · 186910.1002/pola.25955 ↗
23. Geng Y. · Nat. Nanotechnol. · 2007 · 2 · 24910.1038/nnano.2007.70 ↗
24. Shrestha R. · J. Am. Chem. Soc. · 2012 · 134 · 1736210.1021/ja306616n ↗
25. Shrestha R. · Biomaterials · 2012 · 33 · 855710.1016/j.biomaterials.2012.07.054 ↗
26. Samarajeewa S. · Mol. Pharm. · 2013
27. Christian S. · J. Cell Biol. · 2003 · 163 · 87110.1083/jcb.200304132 ↗
28. Reddy G. R. · Clin. Cancer Res. · 2006 · 12 · 667710.1158/1078-0432.CCR-06-0946 ↗
29. Park J. H. · Small · 2009 · 5 · 69410.1002/smll.200801789 ↗
30. Ruoslahti E. · J. Cell Biol. · 2010 · 188 · 75910.1083/jcb.200910104 ↗
31. Orringer D. A. · Neurosurgery · 2009 · 64 · 96510.1227/01.NEU.0000344150.81021.AA ↗
32. Orringer D. A. · Clin. Pharmacol. Ther. · 2009 · 85 · 53110.1038/clpt.2008.296 ↗
33. Heng B. C. · Arch. Toxicol. · 2011 · 85 · 151710.1007/s00204-011-0722-1 ↗
34. Hussain S. · Toxicology · 2009 · 260 · 14210.1016/j.tox.2009.04.001 ↗
35. Rettig L. · Blood · 2010 · 115 · 453310.1182/blood-2009-11-247817 ↗
36. Cui Z. · Mol. Pharm. · 2005 · 2 · 2210.1021/mp049907k ↗
37. Tao W. · Mol Ther · 2011 · 19 · 56710.1038/mt.2010.282 ↗
38. Minigo G. · Vaccine · 2007 · 25 · 131610.1016/j.vaccine.2006.09.086 ↗
39. Fifis T. · J Immunol · 2004 · 173 · 314810.4049/jimmunol.173.5.3148 ↗
40. Mottram P. L. · Mol Pharm · 2007 · 4 · 7310.1021/mp060096p ↗
41. Gao H. · Biomacromolecules · 2010 · 11 · 88910.1021/bm901241k ↗
42. Wei, W.; Lv, P. P.; Chen, X. M.; Yue, Z. G.; Fu, Q.; Liu, S. Y.; Yue, H.; Ma, G. H.Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression.Biomaterials 2013, not supplied.10.1016/j.biomaterials.2013.02.030 ↗
43. George J. · J Cell Mol Med · 2009 · 13 · 420510.1111/j.1582-4934.2008.00539.x ↗
44. Liu W. L. · Cancer Gene Ther. · 2009 · 16 · 76410.1038/cgt.2009.24 ↗
45. Elsabahy M. · Adv. Funct. Mater. · 2009 · 19 · 386210.1002/adfm.200901139 ↗
46. Iversena T. G. · Nano Today · 2011 · 6 · 17610.1016/j.nantod.2011.02.003 ↗
47. Sahay G. · J. Controlled Release · 2010 · 145 · 18210.1016/j.jconrel.2010.01.036 ↗
48. De Haes W. · Mol Pharm · 2012 · 9 · 294210.1021/mp3003336 ↗
49. Rejman J. · Mol. Ther. · 2005 · 12 · 46810.1016/j.ymthe.2005.03.038 ↗
50. Nakamura T. · Acc. Chem. Res. · 2012 · 45 · 111310.1021/ar200254s ↗